Allogene Therapeutics Inc ALLO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
2.73quote price arrow down-0.03 (-1.09%)
Volume
40,914
Close
2.76quote price arrow down-0.10 (-3.50%)
Volume
979,379
52 week range
2.23 - 6.89
Loading...
  • Open2.84
  • Day High2.92
  • Day Low2.74
  • Prev Close2.86
  • 52 Week High6.89
  • 52 Week High Date05/15/23
  • 52 Week Low2.23
  • 52 Week Low Date12/01/23

Key Stats

  • Market Cap471.196M
  • Shares Out170.72M
  • 10 Day Average Volume1.77M
  • Dividend-
  • Dividend Yield-
  • Beta0.89
  • YTD % Change-14.02

KEY STATS

  • Open2.84
  • Day High2.92
  • Day Low2.74
  • Prev Close2.86
  • 52 Week High6.89
  • 52 Week High Date05/15/23
  • 52 Week Low2.23
  • 52 Week Low Date12/01/23
  • Market Cap471.196M
  • Shares Out170.72M
  • 10 Day Average Volume1.77M
  • Dividend-
  • Dividend Yield-
  • Beta0.89
  • YTD % Change-14.02

RATIOS/PROFITABILITY

  • EPS (TTM)-2.09
  • P/E (TTM)-1.32
  • Fwd P/E (NTM)-1.71
  • EBITDA (TTM)-300.292M
  • ROE (TTM)-55.51%
  • Revenue (TTM)94,999.999
  • Gross Margin (TTM)-
  • Net Margin (TTM)-344,489.50%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/13/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Allogene Therapeutics Inc

 

Profile

MORE
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product...
Arie Belldegrun M.D.
Executive Chairman of the Board
David Chang M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
Geoffrey Parker
Chief Financial Officer, Executive Vice President, Principal Financial Officer, and Principal Accounting Officer
Timothy Moore
Executive Vice President, Chief Technical Officer
Zachary Roberts M.D., Ph.D.
Executive Vice President - Research and Development, Chief Medical Officer
Earl Douglas Esq.
General Counsel
Address
210 East Grand Avenue
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
ATXS
Astria Therapeutics Inc
9.73-0.44-4.33%
NKTX
Nkarta Inc
6.25-0.05-0.79%
CMPS
Compass Pathways PLC
7.86-0.68-7.96%
ALT
Altimmune Inc
7.22-0.50-6.48%
KALV
Kalvista Pharmaceuticals Inc
12.08-0.01-0.08%